Pneumococcal vaccine - Intercell/PATH

Drug Profile

Pneumococcal vaccine - Intercell/PATH

Alternative Names: IC 47

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Centers for Disease Control and Prevention; Intercell
  • Developer PATH; Valneva
  • Class Antibacterials; Pneumococcal vaccines; Protein-vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Pneumococcal infections

Most Recent Events

  • 28 May 2013 Intercell has merged with Vivalis to form Valneva
  • 09 Jun 2011 Suspended - Phase-I for Pneumococcal infections in Germany (IM)
  • 12 Feb 2010 Interim safety and immunogenicity data from a phase I trial in healthy volunteers released by Intercell
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top